Rheumatology Advance Access originally published online on April 16, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2003; 42: 893-899
© 2003 British Society for Rheumatology
Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome
Centre for Rheumatology, Department of Medicine, University College London, London, UK
Objectives. Atherosclerosis is an important complication of patients with systemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (APS). One suggested mechanism may be the action of autoantibodies directed against plasma lipoproteins. We studied the presence and patterns of cross-reactivity between antibodies directed against cardiolipin, high-density lipoprotein (HDL) and apolipoprotein A-I (Apo A-I) in patients with SLE and APS.
Methods. Sera from 50 patients (25 SLE and 25 APS) and 10 healthy controls together with three human immunoglobulin G anti-cardiolipin (CL) monoclonal antibodies (IS4, CL1 and CL24) were assessed for the presence of autoantibodies binding cardiolipin, HDL and Apo A-I. Classical inhibition assays were performed to study interference by HDL and Apo A-I in the binding of the human monoclonal antibody to CL. To determine the cross-reactivity patterns between these autoantibodies, sera from 12 patients were incubated on ELISA plates coated with the three different molecules and the captured antibodies were then tested for their activity towards each of the other antigens.
Results. All three monoclonals bound to CL. IS4 and CL1 also bound to HDL but only IS4 bound to Apo A-I. Anti-cardiolipin titres were higher in patients with APS than SLE and in healthy controls (P<0.03 and P<0.009 respectively). Titres of antibodies to HDL were higher in patients with SLE and APS than in controls (P<0.009 and P<0.03 respectively). There were no significant differences with respect to the presence of antibodies binding to Apo A-I. In the SLE population, anti-HDL antibody titres correlated with anti-Apo A-I (r=0.563, P<0.004), but not in patients with APS. In the cross-reactive assay, 11/12 (91.7%) of the samples containing isolated anti-CL antibodies reacted to HDL and 2/12 (16.7%) to Apo A-I. Samples containing isolated anti-HDL antibodies also reacted with CL and Apo A-I (7/12 and 3/12 respectively). All samples collected after incubation with Apo A-I bound to HDL and 6/12 (50%) to CL. There were no differences in the cross-reactivity patterns between patients with SLE and APS.
Conclusions. Patients with SLE and APS have antibodies directed against HDL and Apo A-I. A high percentage of these antibodies cross-react with CL, suggesting the presence of different groups of antibodies with different targets. The study of the interaction between the immune response and the lipoprotein components and the correct characterization of the reactivity patterns of autoantibodies may be of relevance in the study of atherosclerosis in patients with SLE and APS.
KEY WORDS: Systemic lupus erythematosus, Antiphospholipid syndrome, Atherosclerosis, Anti-HDL, Anti-Apo A-I, Cross-reactivity.
Correspondence to: J. Delgado Alves, Windeyer Institute of Medical Sciences, Centre for Rheumatology, Room 118, 46 Cleveland Street, London, UK. E-mail: j.alves{at}ucl.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Charakida, C. Besler, J. R. Batuca, S. Sangle, S. Marques, M. Sousa, G. Wang, D. Tousoulis, J. Delgado Alves, S. P. Loukogeorgakis, et al. Vascular Abnormalities, Paraoxonase Activity, and Dysfunctional HDL in Primary Antiphospholipid Syndrome JAMA, September 16, 2009; 302(11): 1210 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ahmad, J. Shelmerdine, H. Bodill, M. Lunt, M. G. Pattrick, L. S. Teh, R. M. Bernstein, M. G. Walker, and I. N. Bruce Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype Rheumatology, June 1, 2007; 46(6): 983 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N. Bruce 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus Rheumatology, December 1, 2005; 44(12): 1492 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shoenfeld, R. Gerli, A. Doria, E. Matsuura, M. M. Cerinic, N. Ronda, L. J. Jara, M. Abu-Shakra, P. L. Meroni, and Y. Sherer Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases Circulation, November 22, 2005; 112(21): 3337 - 3347. [Full Text] [PDF]
|
|
|
|
 |
|
 I N Bruce Atherogenesis and autoimmune disease: the model of lupus Lupus, September 1, 2005; 14(9): 687 - 690. [Abstract] [PDF]
|
|
|
|
|
|
C. Gorman and D. Isenberg Atherosclerosis and lupus Rheumatology, August 1, 2004; 43(8): 943 - 945. [Full Text] [PDF]
|
|